SEC Form SC 13G filed by Verve Therapeutics Inc.

$VERV
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $VERV alert in real time by email
SC 13G 1 Verve_Therapeutics_Inc.htm SCHEDULE 13G Amendment No. 15

 

  SECURITIES AND EXCHANGE COMMISSION  
  Washington, D.C. 20549  
 
SCHEDULE 13G
 
 
Under the Securities Exchange Act of 1934
 
(Amendment No. )*
 

VERVE THERAPEUTICS INC

(Name of Issuer)
 

COMMON STOCK

(Title of Class of Securities)
 

92539P101

(CUSIP Number)
 

September 30, 2024

(Date of Event Which Requires Filing of This Statement)
 
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
ý Rule 13d-1(b)
¨ Rule 13d-1(c)
¨ Rule 13d-1(d)
 
(Page 1 of 5 Pages)

 

______________________________

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 

 

 

 

92539P101 13G Page 2 of 5 Pages

 

1

NAME OF REPORTING PERSON

STATE STREET CORPORATION

I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: 04-2456637

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) ¨

(b) ¨

3 SEC USE ONLY
4

CITIZENSHIP OR PLACE OF ORGANIZATION

MA

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5

SOLE VOTING POWER

0

6

SHARED VOTING POWER

4,060,913

7

SOLE DISPOSITIVE POWER

0

8

SHARED DISPOSITIVE POWER

4,253,217

9

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

4,253,217.00

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
11

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.0%

12

TYPE OF REPORTING PERSON

HC

         

 

 

 

92539P101 13G Page 3 of 5 Pages

 

Item 1(a). NAME OF ISSUER
   
  VERVE THERAPEUTICS INC

 

Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES
   
  500 TECHNOLOGY SQ STE 901 CAMBRIDGE MA 02139 UNITED STATES

 

Item 2(a). NAME OF PERSON FILING
   
 

STATE STREET CORPORATION

 

Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE
   
  ONE CONGRESS STREET, SUITE 1, BOSTON MA 02114, UNITED STATES

 

Item 2(c). CITIZENSHIP
   
  MA

 

Item 2(d). TITLE OF CLASS OF SECURITIES
   
  COMMON STOCK

 

Item 2(e). CUSIP NUMBER
   
  92539P101

 

Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§240.13d-1(b), OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

 

STATE STREET CORPORATION (a) Broker or dealer registered under Section 15 of the Act;
  (b) Bank as defined in Section 3(a)(6) of the Act;
  (c) Insurance company as defined in Section 3(a)(19) of the Act;
  (d) Investment company registered under Section 8 of the Investment Company Act of 1940;
  (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
  (f)

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

 

  (g) X

A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

 

  (h)

A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

 

  (i)

A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

 

  (j) A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
  (k) Group, in accordance with §240.13d-1(b)(1)(ii)(K).
  If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

 

 

92539P101 13G Page 4 of 5 Pages

 

Item 4. OWNERSHIP
   
  Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
  (a) Amount beneficially owned: 4,253,217.00  
  (b) Percent of class: 5.0%  
  (c) Number of shares as to which the person has:    
         
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote 4,060,913
    (iii) Sole power to dispose or to direct the disposition of 0
    (iv) Shared power to dispose or to direct the disposition of 4,253,217
         
  Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

 

Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
  If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following
  ¨
  Instruction: Dissolution of a group requires a response to this item.

 

Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
   
  NOT APPLICABLE

 

Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY OR CONTROL PERSON
   
  SSGA FUNDS MANAGEMENT, INC. (IA) STATE STREET GLOBAL ADVISORS EUROPE LIMITED (IA) STATE STREET GLOBAL ADVISORS LIMITED (IA) STATE STREET GLOBAL ADVISORS TRUST COMPANY (IA) STATE STREET GLOBAL ADVISORS, LTD. (IA)

 

Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
   
  NOT APPLICABLE

 

Item 9. NOTICE OF DISSOLUTION OF GROUP
   
  NOT APPLICABLE

 

Item 10. CERTIFICATION

 

  By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11
   

 

 

 

92539P101 13G Page 5 of 5 Pages

 

SIGNATURES

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.

DATE: October 14, 2024

 

   
     
     
    ELIZABETH SCHAEFER, SENIOR VICE PRESIDENT, CHIEF ACCOUNTING OFFICER
     
     

 

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

 

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties for whom copies are to be sent.

 

Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

 

Get the next $VERV alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$VERV

DatePrice TargetRatingAnalyst
4/8/2024$15.00Buy
H.C. Wainwright
4/13/2023$29.00Buy
Canaccord Genuity
2/1/2023$21.00Neutral
Cantor Fitzgerald
12/15/2022$13.00Sell
Goldman
10/6/2022$48.00Neutral
Credit Suisse
8/25/2022$32.00 → $56.00Hold → Buy
Stifel
6/17/2022$48.00Outperform
BMO Capital Markets
2/18/2022$42.00Outperform
RBC Capital
More analyst ratings

$VERV
Press Releases

Fastest customizable press release news feed in the world

See more
  • Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose

    BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for VERVE-102 for the treatment of patients living with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD). VERVE-102 is a novel, investigational in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C). "The IND clearance from the U.S. F

    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on February 28, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options to purchase an aggregate of 14,300 shares of the company's common stock and an aggregate of 20,100 restricted stock units (RSUs). The options have an exercise price of $6.33 per share, which is eq

    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results

    Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025 VERVE-102 has been well-tolerated, with no treatment-related serious adverse events and no clinically significant laboratory abnormalities observed Delivery of opt-in package to Eli Lilly and an opt-in decision from Lilly expected in the second half of 2025 Enrollment ongoing in Pulse-1 Phase 1b clinical trial of VERVE-201 targeting ANGPTL3 Cash, cash equivalents, and marketable securities of $524.3 million; cash runway into mid-2027 BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- V

    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VERV
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$VERV
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$VERV
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$VERV
SEC Filings

See more

$VERV
Leadership Updates

Live Leadership Updates

See more
  • Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical Officer

    BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick "Fred" T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO. "We are excited by the continued expansion of the Verve team and the execution of a plan to become a multi-product clinical-stage company," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "Our heart-1 clinical trial is well underway, wi

    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Verve Therapeutics Appoints Experienced Biotechnology Executive, Alexander G. "Bo" Cumbo, to its Board of Directors

    CAMBRIDGE, Mass., June 13, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Alexander G. "Bo" Cumbo, chief executive officer and president of AavantiBio, Inc., has joined the company's board of directors. "Bo is a highly experienced industry executive with a well-established track record of leading pharmaceutical and life sciences companies through critical processes in drug development and commercial execution," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve. "As we focus on continued execution of our regulatory

    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer

    CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (NASDAQ:VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Allison Dorval has been appointed as chief financial officer. Ms. Dorval joins Verve from Voyager Therapeutics and brings more than 20 years of leadership experience in finance, accounting, financial reporting and investor relations. "Allison joins Verve at an exciting stage of our company's evolution, on the heels of a successful IPO earlier this year and recent preclinical data updates from our lead programs targeting PCSK9 and ANGPTL3 as base editing

    $VERV
    Biotechnology: Pharmaceutical Preparations
    Health Care

$VERV
Financials

Live finance-specific insights

See more

$VERV
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more